Why Pediatric Research needs "Insights"

Olaf Dammann,Cynthia Bearer

DOI: https://doi.org/10.1038/s41390-023-02983-7

IF: 3.953

2024-01-18

Pediatric Research

Abstract:Pediatric Research, Published online: 17 January 2024; doi:10.1038/s41390-023-02983-7 Why Pediatric Research needs "Insights"

pediatrics

What problem does this paper attempt to address?

How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Eva Neumann,Filippa Schreeck,Jethro Herberg,Evelyne Jacqz Aigrain,Anke H Maitland-van der Zee,Antonio Pérez-Martínez,Daniel B Hawcutt,Elke Schaeffeler,Anders Rane,Saskia N de Wildt,Matthias Schwab

DOI: https://doi.org/10.1111/bcp.15216

Abstract:The safety and efficacy of pharmacotherapy in children, particularly preterms, neonates and infants, is limited by a paucity of good-quality data from prospective clinical drug trials. A specific challenge is the establishment of valid biomarkers. OMICs technologies may support these efforts by complementary information about targeted and nontargeted molecules through systematic characterization and quantitation of biological samples. OMICs technologies comprise at least genomics, epigenomics, transcriptomics, proteomics, metabolomics and microbiomics in addition to the patient's phenotype. OMICs technologies are in part hypothesis-generating, allowing an in depth understanding of disease pathophysiology and pharmacological mechanisms. Application of OMICs technologies in paediatrics faces major challenges before routine adoption. First, developmental processes need to be considered, including a subdivision into specific age groups as developmental changes clearly impact OMICs data. Second, compared to the adult population, the number of patients is limited as are the type and amount of necessary biomaterial, especially in neonates and preterms. Thus, advanced trial designs and biostatistical methods, noninvasive biomarkers, innovative biobanking concepts including data and samples from healthy children, as well as analytical approaches (eg liquid biopsies) should be addressed to overcome these obstacles. The ultimate goal is to link OMICs technologies with innovative analysis tools, such as artificial intelligence at an early stage. The use of OMICs data based on a feasible approach will contribute to the identification complex phenotypes and subpopulations of patients to improve the development of medicines for children with potential economic advantages.
Pediatric Research ECI highlight: Matthew S. Pantell

Matthew S. Pantell

DOI: https://doi.org/10.1038/s41390-024-03214-3

IF: 3.953

2024-04-27

Pediatric Research

Abstract:Pediatric Research, Published online: 25 April 2024; doi:10.1038/s41390-024-03214-3 Pediatric Research ECI highlight: Matthew S. Pantell

pediatrics
Research in pediatric oncology: Engaging parents to strengthen research processes, outcomes and knowledge translation

Jill M G Bally,Solomon K Mcharo

2020-07-01

Abstract:Childhood cancer is the most common disease-related cause of death in Canadian children aged 0-14 years, with more than 1,000 new diagnoses every year (Canadian Cancer Statistics Advisory Committee, 2019). Treatment for childhood cancers requires complex, intensive, and lengthy regimens, often lasting years. Each new diagnosis marks tremendous upheaval in the lives of the child and their family, and an opportunity for nurses in pediatric oncology to make a difference. However, to best intervene, it is crucial to understand the experiences and needs of parental caregivers who have children in treatment for cancer. Patient Oriented Research is one way to bring together patients, family members, researchers, healthcare providers, and decision-makers to actively collaborate, understand best practices, and create transformational positive change in pediatric oncology.
Pediatric Rare Diseases Development in the Pharmaceutical Industry: An International Consortium for Innovation and Quality in Pharmaceutical Development, Clinical Pharmacology Leadership Group‐Pediatrics Working Group, Rare Diseases Subteam Whitepaper Examining the Current Landscape and Recommendations for the Future

Rajesh Krishna,Bernard Sebastien,Solange Corriol‐Rohou,S. Y. Amy Cheung,Jing Liu,Satyendra Suryawanshi

DOI: https://doi.org/10.1002/cpt.3422

2024-08-15

Clinical Pharmacology & Therapeutics

Abstract:Many new opportunities surround rare pediatric disease drug development, thanks to key advances in regulatory thinking and in the scientific community. As rare disease drug development brings challenges to the developers in terms of limited understanding of natural history, heterogeneity in drug response, as well as difficulty recruiting patients in pivotal trials, there has never been a greater need for quantitative integration. To understand how International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) member companies approach pediatric rare disease drug development, the rare pediatric subteam of the Clinical Pharmacology Leadership Group (CPLG) sponsored Pediatrics Working Group conducted a baseline survey to assess the four main pillars of this quantitative innovation, namely, biomarkers and surrogate end points, statistical methodologies, model‐informed drug development, as well as public–private partnerships. The survey was administered by IQ and yielded 13 evaluable responders from represented companies. This article presents the key findings from this baseline identifying survey, highlighting the key blind spots, and providing insightful expert opinions to address those gaps. In summary, we call an urgent attention to the community on the opportunities to enhance integration and within‐industry learnings from this analysis on aspects related to platform studies, end‐to‐end quantitative integration, and sharing of trial‐level placebo data for better understanding of disease progression and more efficient trial designs. We collectively hope that these findings will stimulate discussion and debate around cross‐industry sharing and collaboration to better delineate principles and further enhance the efficiency of rare pediatric disease drug development.

pharmacology & pharmacy
[PERSPECTIVES] Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress

Rosane Charlab,Ruby Leong,Stacy S. Shord,Gregory H. Reaman

DOI: https://doi.org/10.1101/cshperspect.a041656

2024-04-02

Cold Spring Harbor Perspectives in Medicine

Abstract:The discovery and development of anticancer drugs for pediatric patients have historically languished when compared to both past and recent activity in drug development for adult patients, notably the dramatic spike of targeted and immune-oncology therapies. The reasons for this difference are multifactorial. Recent changes in the regulatory landscape surrounding pediatric cancer drug development and the understanding that some pediatric cancers are driven by genetic perturbations that also drive disparate adult cancers afford new opportunities. The unique cancer-initiating events and dependencies of many pediatric cancers, however, require additional pediatric-specific strategies. Research efforts to unravel the underlying biology of pediatric cancers, innovative clinical trial designs, model-informed drug development, extrapolation from adult data, addressing the unique considerations in pediatric patients, and use of pediatric appropriate formulations, should all be considered for efficient development and dosage optimization of anticancer drugs for pediatric patients.

medicine, research & experimental
COVID-19 impact on research, lessons learned from COVID-19 research, implications for pediatric research

Debra L. Weiner,Vivek Balasubramaniam,Shetal I. Shah,Joyce R. Javier,

DOI: https://doi.org/10.1038/s41390-020-1006-3

IF: 3.953

2020-06-16

Pediatric Research

Abstract:Pediatric Research, Published online: 16 June 2020; <a href="https://www.nature.com/articles/s41390-020-1006-3">doi:10.1038/s41390-020-1006-3</a>COVID-19 impact on research, lessons learned from COVID-19 research, implications for pediatric research

pediatrics
Making the case for pediatric research: a life-cycle approach and the return on investment

Daniel P. Gitterman,William W. Hay,W. Scott Langford

DOI: https://doi.org/10.1038/s41390-022-02141-5

IF: 3.953

2022-07-12

Pediatric Research

Abstract:There is unmistakable evidence of increased NIH funding for pediatric and perinatal research, but there is much work to be done. To further promote NIH-funded pediatric and perinatal research, we advocate for a life-cycle approach in which the return on the investment continues over the lifespan. Although elected policymakers have short-time horizons, pediatric and perinatal researchers must provide novel evidence and theoretical arguments demonstrating the long-term health benefits for the adults of tomorrow by improving the health of our current pediatric populations. Child health researchers must communicate the role of early developmental events on childhood and adult disease, including those that are prenatal and gestational so that its importance is understood by the public and policymakers.

pediatrics
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group

Athimalaipet V Ramanan,Neena Modi,Saskia N de Wildt,c4c Learning from COVID-19 Group,Beate Aurich,Sophia Bakhtadze,Francisco J Bautista Sirvent,Fernando Cabañas,Lisa Campbell,Michaela Casanova,Philippa Charlton,Wallace Crandall,Irmgard Eichler,Laura Fregonese,Daniel B Hawcutt,Pablo Iveli,Thomas Jaki,Bosanka Jocic-Jakubi,Mats Johnson,Florentina Kaguelidou,Bülent Karadag,Lauren E Kelly,Ming Lim,Carmen Moreno,Eva Neumann,Cécile Ollivier,Mehdi Oualha,Genny Raffaeli,Maria A Ribeiro,Emmanuel Roilides,Teresa de Rojas,Alba Rubio San Simón,Nicolino Ruperto,Maurizio Scarpa,Matthias Schwab,Angeliki Siapkara,Yogen Singh,Anne Smits,Pasquale Striano,Silvana A M Urru,Marina Vivarelli,Saskia de Wildt,Zorica Zivkoviz

DOI: https://doi.org/10.1038/s41390-021-01587-3

Abstract:Background: The COVID-19 pandemic has had a devastating impact on multiple aspects of healthcare, but has also triggered new ways of working, stimulated novel approaches in clinical research and reinforced the value of previous innovations. Conect4children (c4c, www.conect4children.org ) is a large collaborative European network to facilitate the development of new medicines for paediatric populations, and is made up of 35 academic and 10 industry partners from 20 European countries, more than 50 third parties, and around 500 affiliated partners. Methods: We summarise aspects of clinical research in paediatrics stimulated and reinforced by COVID-19 that the Conect4children group recommends regulators, sponsors, and investigators retain for the future, to enhance the efficiency, reduce the cost and burden of medicines and non-interventional studies, and deliver research-equity. Findings: We summarise aspects of clinical research in paediatrics stimulated and reinforced by COVID-19 that the Conect4children group recommends regulators, sponsors, and investigators retain for the future, to enhance the efficiency, reduce the cost and burden of medicines and non-interventional studies, and deliver research-equityWe provide examples of research innovation, and follow this with recommendations to improve the efficiency of future trials, drawing on industry perspectives, regulatory considerations, infrastructure requirements and parent-patient-public involvement. We end with a comment on progress made towards greater international harmonisation of paediatric research and how lessons learned from COVID-19 studies might assist in further improvements in this important area.
A new paradigm in bench to bedside research, with a stop in the dusty pharmaceutical cabinet?

Vivek Balasubramaniam,Lois K. Lee,Joyce R. Javier

DOI: https://doi.org/10.1038/s41390-021-01482-x

IF: 3.953

2021-04-06

Pediatric Research

Abstract:Pediatric Research, Published online: 06 April 2021; <a href="https://www.nature.com/articles/s41390-021-01482-x">doi:10.1038/s41390-021-01482-x</a>A new paradigm in bench to bedside research, with a stop in the dusty pharmaceutical cabinet?

pediatrics
The indirect effects of COVID-19 on pediatric research

Stephen J. Teach,Joseph W. St. Geme

DOI: https://doi.org/10.1038/s41390-021-01563-x

IF: 3.953

2021-05-07

Pediatric Research

Abstract:Pediatric Research, Published online: 07 May 2021; <a href="https://www.nature.com/articles/s41390-021-01563-x">doi:10.1038/s41390-021-01563-x</a>The indirect effects of COVID-19 on pediatric research

pediatrics
Research capacity and limitations in Canadian paediatric emergency departments: An observational study on biomarker discovery

Elena Mitevska,Beata Mickiewicz,Leslie Boisvert,Christine Bon,Redjana Carciumaru,Ramona Cook,Tyrus Crawford,Joan Dietz,Melanie Doyle,Angela Y Hui,Karly Stillwell,Adriana Trajtman,Darcy Beer,Maala Bhatt,William Craig,Eleanor Fitzpatrick,Jocelyn Gravel,April Kam,Ahmed Mater,Anne Moffat,Naveen Poonai,Vikram Sabhaney,Graham C Thompson

DOI: https://doi.org/10.1093/pch/pxae023

2024-07-24

Paediatrics & Child Health

Abstract:Abstract Background Paediatric research is essential to acquire effective diagnoses and treatment for children, but it has historically been under-prioritized. The PRIMED study aimed to characterize the bio-profiles of children with appendicitis and investigate their use as a clinical prediction tool. We evaluated the clinical research capacity of several Canadian paediatric emergency departments (EDs) and described both the challenges experienced in the implementation of the PRIMED study and the strategies which were used to improve local research capacity. Methods Eleven paediatric EDs across Canada provided basic demographic and administrative data along with laboratory- and human-resource availability during the PRIMED study enrollment. Data were summarized using descriptive statistics. Results Fewer than half of the study sites (5/11, 45%) had access to a laboratory that would process research samples 24 hours per day. Four study sites (36%) only enrolled patients during business hours (8:00–17:00). There was no nighttime coverage for patient enrollment and sample collection. Only three study sites (27%) had enrollment hours that captured over 75% of the potential study participants. Over half of the study sites (6/11, 55%) developed novel processes to enable study success, for example, creating graduate student on-call schedules and hiring bioscience-trained site coordinators to process samples. Interpretation Despite site-specific efforts to overcome resource barriers, the gap in clinical research capacity at academic paediatric EDs remains a significant concern. University research institutes and paediatric hospitals should invest in infrastructure and human resources to increase after-hours research capacity to optimize child health and wellness outcomes.

pediatrics
Viewpoint: digital paediatrics-so close yet so far away

Kai O Hensel,John Powell

DOI: https://doi.org/10.1136/archdischild-2021-322719

Abstract:Technology is driving a revolution in healthcare, but paediatric services have not fully harnessed the potential. Digital health solutions yet to achieve their promise in paediatrics include electronic health records, decision support systems, telemedicine and remote consultations, despite the accelerated uptake during the COVID-19 pandemic. There are also significant potential benefits in digitally enabled research, including systems to identify and recruit participants online or through health records, tools to extract data points from routine data sets rather than new data collection, and remote approaches to outcome measurement. Children and their families are increasingly becoming digital health citizens, able to manage their own health and use of health services through mobile apps and wearables such as fitness trackers. Ironically, one barrier to the uptake of these technologies is that the fast pace of change in this area means the evidence base behind many of these tools remains underdeveloped. Clinicians are often sceptical of innovations which appear largely driven by enthusiasts rather than science. Rigorous studies are needed to demonstrate safety and effectiveness. Regulators need to be agile and responsive. Implementation needs adequate resource and time, and needs to minimise risks and address concerns, such as worries over losing human contact. Digital health care needs to be embedded in medical education and training so that clinicians are trained in the use of innovations and can understand how to embed within services. In this way, digital paediatrics can deliver benefits to the profession, to services and to our patients.
Far from idle: Four ways in which growing knowledge of the 'resting' brain is transforming our understanding of the causes of childhood disorder

Edmund J S Sonuga-Barke

DOI: https://doi.org/10.1111/jcpp.12359

Abstract:Historians of science continue to debate the importance of individual inspiration and personal creativity as fuel in the engine of scientific progress. While true that, in general, scientific knowledge advances cautiously by careful experimentation, painstaking observation and the gradual accumulation of evidence occasionally a field of enquiry can be revolutionised by a single, perhaps simple, yet inspired and profound insight. Such breakthroughs are most likely to occur when an individual moves outside the intellectual tramlines that normally constrain scientific thinking, leaving them able to look at old evidence in new and original ways. The reception of such original insights by the research community varies considerably, of course. Some insights may be 'too original'--a step too far in what is normally an incremental journey of discovery. Some ideas, enthusiastically accepted initially, may burn out before making any real impression. Other ideas revolutionize a field--producing a cascade of hypotheses and lines of enquiry that lead to new discoveries which permanently change the scientific landscape. The issue of scientific creativity was very much in my mind when reading through the papers slated to appear in the current journal number. One article in particular, by Pannekoeke and colleagues on intrinsic brain organisation in depressed adolescents, initiated a chain of thought that led me to my focus for this editorial. A development that provides perhaps the most compelling recent example of the transformative power of individual inspiration in the field of cognitive neuroscience--a development which is also beginning to have profound implications for models of childhood mental disorders.
Elevating pediatric urology care: The crucial role of nursing research in quality improvement

Anka J. Nieuwhof-Leppink,Massimo Garriboli,Salvatore Cascio,Luis H. Braga,Bernhard Haid,Caleb P. Nelson,Muhammet Irfan Dönmez,Christina B. Ching,Luke Harper,the ESPU Research Committee

DOI: https://doi.org/10.1016/j.jpurol.2024.01.032

IF: 1.921

2024-02-17

Journal of Pediatric Urology

Abstract:Summary This educational article highlights the critical role of pediatric urology nursing research in improving the care of children with urological conditions. It discusses the multifaceted nature of pediatric urology nursing, addresses challenges such as limited nurse scientists and resource constraints, and highlights the need to overcome barriers to increase research involvement. The authors emphasize the importance of prioritizing research areas, the promotion of collaboration, and the provision of adequate funding and academic time for pediatric nurses to contribute to evidence-based practice, to improve patient outcomes. Furthermore, it highlights the importance of research in advancing nursing practice, shaping protocols, and advocating for the rights and needs of children with urological conditions and their families.

pediatrics,urology & nephrology
Reflections on the regulatory field covering the development of paediatric medicinal products: a brief overview of current status and challenges

Birka Lehmann

DOI: https://doi.org/10.3389/fphar.2024.1375988

IF: 5.6

2024-06-03

Frontiers in Pharmacology

Abstract:Many medicinal products are initially developed and tested in adults, and often, only a limited amount of data on their safety and efficacy in children exist. Consequently, paediatric healthcare providers sometimes need to make informed decisions about using medicinal products in children based on available fragmentary data. Ethical guidelines emphasise the importance of protecting children and ensuring they receive safe and effective medical treatments. Paediatric clinical trials should be conducted to provide evidence-based care with specific attention to minimise risks to children. This highlights the dilemma of finding a balance between protecting children and adolescents (and avoiding unnecessary clinical trials) and obtaining reliable, robust and justified data to treat them adequately and not in an off-label manner with unknown risks. For years, paediatricians maintained that children and adolescents are not treated based on up-to-date scientific knowledge and justification. The slogan "children are not small adults" summarised the concerns in a catch phrase. Different stakeholders have taken a variety of actions to address this concern.

pharmacology & pharmacy
Pediatric subspecialty workforce: what is needed to secure its vitality and survival?

Christiane E. Dammann,Cristina M. Alvira,Sherin U. Devaskar,Joseph W. St. Geme III,W. Christopher Golden,Catherine M. Gordon,Benjamin Hoffmann,Satyan Lakshminrusimha,Laurel K. Leslie,Maria Trent,Karen K. Winer,H. Barrett Fromme

DOI: https://doi.org/10.1038/s41390-024-03607-4

IF: 3.953

2024-10-26

Pediatric Research

Abstract:The pediatric subspecialty workforce is challenged by shortages and geographic maldistribution of subspecialists. We invited leaders in pediatrics to discuss how the field's vitality and survival can be secured. These leaders presented their own opinions and not the opinion of the society or organization that they are presenting. Early exposure of future trainees to pediatrics and advocacy for improved reimbursement structures, loan repayment, and funded programs for physician scientists will enhance the recruitment and retention of pediatric subspecialists to guarantee advancement of knowledge and the appropriate care of children with chronic and complex diseases.

pediatrics
Pediatric Assent in Clinical Practice: A Critical Scoping Review

Jason Adam Wasserman,Amelia N Najor,Natalie Liogas,Stephanie M Swanberg,Abram Brummett,Naomi T Laventhal,Mark Christopher Navin

DOI: https://doi.org/10.1080/23294515.2024.2388517

Abstract:Background: This study assesses how pediatric assent is conceptualized and justified within the therapeutic context. Pediatric ethicists generally agree that children should participate in medical care decisions in developmentally appropriate ways. Much attention has been paid to pediatric assent for research participation, but ambiguities persist in how assent is conceptualized and operationalized in the therapeutic context where countervailing considerations such as the child's best interest and parental permission must also be weighed. Methods: Searches were conducted in 11 databases including PubMed, Embase, Cochrane Library, and Web of Science. Articles published between 2010 and 2020 were screened in COVIDENCE for meeting each of four criteria: (1) focusing on pediatric assent, (2) focusing on clinical care, (3) including normative claims, and (4) containing substantive statements about the meaning of pediatric assent. Full texts were abstracted for (1) operational definitions of assent, (2) discussion of the temporal nature of assent, (3) description of the concept of "understanding," and (4) ethical justifications for soliciting assent. These excerpts were coded and code patterns formed themes presented in the results. Results: The final analytic data set contained 29 articles. Analysis yielded three key themes. First, valid assent varies by treatment, population (e.g., younger versus older), and geographic/cultural context. Second, assent represents two distinct longitudinal processes: One involves eliciting preferences over a disease course or care episode; the other focuses on children's developmental maturation. Third, ethical justifications for assent draw variously on instrumental and intrinsic reasons, but often remain ambiguous. Conclusions: There is widespread agreement that assent is morally valuable, but there remain substantial ambiguities or disagreements about its meaning, process, and ethical justification.
Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks

Katusra Tsukamoto,Kelly A Carroll,Taku Onishi,Naoki Matsumaru,Daniel Brasseur,Hidefumi Nakamura

DOI: https://doi.org/10.1016/j.clinthera.2016.01.012

Abstract:Purpose: A dearth in pediatric drug development often leaves pediatricians with no alternative but to prescribe unlicensed or off-label drugs with a resultant increased risk of adverse events. We present the current status of pediatric drug development and, based on our data analysis, clarify the problems in this area. Further action is proposed to improve the drug development that has pediatric therapeutic orphan status. Methods: We analyzed all Phase II/III and Phase III trials in ClinicalTrials.gov that only included pediatric participants (<18 years old) between 2006 and 2014. Performance index, an indicator of pediatric drug development, was calculated by dividing the annual number of pediatric clinical trials by million pediatric populations acquired from Census.gov. Effects of the 2 Japanese premiums introduced in 2010, for the enhancement of pediatric drug development, were analyzed by comparing mean performance index prepremiums (2006-2009) and postpremiums (2010-2014) among Japan, the European Union, and the United States. The European Union Clinical Trials Register and published reports from the European Medicines Agency were also surveyed to investigate the Paediatric Committee effect on pediatric clinical trials in the European Union. Findings: Mean difference of the performance index in prepremiums and postpremiums between Japan and the European Union were 0.296 (P < 0.001) and 0.066 (P = 0.498), respectively. Those between Japan and the United States were 0.560 (P < 0.001) and 0.281 (P = 0.002), indicating that pediatric drug development in Japan was more active after the introduction of these premiums, even reaching the level of the European Union. The Pediatric Regulation and the Paediatric Committee promoted pediatric drug development in the European Union. The registered number of clinical trials that includes at least 1 participants <18 years old in the European Union Clinical Trials Register increased by 247 trials (from 672) in the 1000 days after regulation. The ratio of pediatric clinical trials with an approved Paediatric Investigation Plan increased to >15% after 2008. Implications: Recruitment and ethical obstacles make conducting pediatric clinical trials challenging. An improved operational framework for conducting clinical trials should mirror the ever-improving regulatory framework that incentivizes investment in pediatric clinical trials. Technological approaches, enhancements in electronic medical record systems, and community approaches that actively incorporate input from physicians, researchers, and patients could offer a sustainable solution to recruitment of pediatric study participants. The key therefore is to improve pediatric pharmacotherapy collaboration among industry, government, academia, and community. Expanding the regulatory steps taken in the European Union, United States, and Japan and using innovative clinical trial tools can move pediatric pharmacotherapy out of its current therapeutic orphan state.
PEDSnet: how a prototype pediatric learning health system is being expanded into a national network

Christopher B Forrest,Peter Margolis,Michael Seid,Richard B Colletti

DOI: https://doi.org/10.1377/hlthaff.2014.0127

Abstract:Except for a few conditions, pediatric disorders are rare diseases. Because of this, no single institution has enough patients to generate adequate sample sizes to produce generalizable knowledge. Aggregating electronic clinical data from millions of children across many pediatric institutions holds the promise of producing sufficiently large data sets to accelerate knowledge discovery. However, without deliberately embedding these data in a pediatric learning health system (defined as a health care organization that is purposefully designed to produce research in routine care settings and implement evidence at the point of care), efforts to act on this new knowledge, reducing the distress and suffering that children experience when sick, will be ineffective. In this article we discuss a prototype pediatric learning health system, ImproveCareNow, for children with inflammatory bowel disease. This prototype is being scaled up to create PEDSnet, a national network that will support the efficient conduct of clinical trials, observational research, and quality improvement across diseases, specialties, and institutions.
Recent landscape and trends for industry-sponsored pediatric clinical trials in China from 2013 to 2022

Chang Liu,Yi Liu,Ling Ou,Yuenan Qi,Jianmin Zhang

DOI: https://doi.org/10.1002/ped4.12409

2024-01-03

Abstract:Importance: Pediatric medication is a challenging issue globally. Promoting trials of medications for children and implementing measures to encourage innovation for addressing unmet medical and health needs are important. Objective: To explore the recent landscape of pediatric clinical trials of new investigational drugs conducted by pharmaceutical enterprises in China from 2013 to 2022 to provide insight into pediatric drug development in the pharmaceutical industry and regulatory policy formulation. Methods: We performed a cross-sectional observational investigation of pediatric clinical trials registered from January 1, 2013, to December 31, 2022, on the Registration and Information Disclosure Platform for Drug Clinical Trials, the official registration platform established in 2013 for trials of new investigational drugs initiated by biopharmaceutical enterprises. Trials that included pediatric participants (under 18 years old) were retrieved, and their relevant characteristics were extracted and analyzed. Results: In total, 895 pediatric clinical trials were collected, accounting for 5.1% of the total registered clinical trials initiated prior to January 1, 2023. The overall average annual growth rate for the number of pediatric clinical trials was 12% (P < 0.001). Phase III trials accounted for the highest proportion (49.1%, 439). Of the 895 trials included, 736 (82.2%) were domestic trials, and 159 (17.8%) were international multicenter trials. In terms of tested drugs, investigations of biological products accounted for the largest proportion of trials (67.4%, 603). Among pediatric clinical trials, studies of vaccines accounted for the largest proportion of trials (41.0%, 367), followed by trials for rare diseases (17.2%, 154). Furthermore, geographical distribution analysis revealed that the largest and smallest numbers of trials were conducted in North China (35.7%, 320) and Northeast China (0.8%, 7), respectively. Interpretation: The growth trends for industry-sponsored clinical trials involving children illustrate the progress and increasing capability of pediatric drug development achieved in China since 2013. Current challenges and potential areas of focus for policymakers and stakeholders include investigating orphan drugs for rare diseases according to the unique epidemiological characteristics of Chinese children, expanding the scope of pediatric clinical trials, and improving the uneven geographical distribution of leading research centers.

Why Pediatric Research needs "Insights"

How paediatric drug development and use could benefit from OMICs: A c4c expert group white paper

Pediatric Research ECI highlight: Matthew S. Pantell

Research in pediatric oncology: Engaging parents to strengthen research processes, outcomes and knowledge translation

[PERSPECTIVES] Pediatric Cancer Drug Development: Leveraging Insights in Cancer Biology and the Evolving Regulatory Landscape to Address Challenges and Guide Further Progress

COVID-19 impact on research, lessons learned from COVID-19 research, implications for pediatric research

Making the case for pediatric research: a life-cycle approach and the return on investment

Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group

A new paradigm in bench to bedside research, with a stop in the dusty pharmaceutical cabinet?

The indirect effects of COVID-19 on pediatric research

Research capacity and limitations in Canadian paediatric emergency departments: An observational study on biomarker discovery

Viewpoint: digital paediatrics-so close yet so far away

Far from idle: Four ways in which growing knowledge of the 'resting' brain is transforming our understanding of the causes of childhood disorder

Elevating pediatric urology care: The crucial role of nursing research in quality improvement

Reflections on the regulatory field covering the development of paediatric medicinal products: a brief overview of current status and challenges

Pediatric subspecialty workforce: what is needed to secure its vitality and survival?

Pediatric Assent in Clinical Practice: A Critical Scoping Review

Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks

PEDSnet: how a prototype pediatric learning health system is being expanded into a national network

Recent landscape and trends for industry-sponsored pediatric clinical trials in China from 2013 to 2022